NCT06179836 (CSBIT) is a clinical trial in Severe Brain Injury, sponsored by Xuanwu Hospital, Beijing.

Who is sponsoring NCT06179836?

NCT06179836 is sponsored by Xuanwu Hospital, Beijing.

What condition does NCT06179836 study?

NCT06179836 studies Severe Brain Injury.

Is NCT06179836 still recruiting?

NCT06179836 is currently not yet recruiting. Last updated 22 December 2023.

Last reviewed 2023-12-22 · How we verify

NCT06179836: CSBIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chinese Severe Brain Injury Trial

Not yet recruiting Last updated 22 December 2023

What this trial tests

trial in Severe Brain Injury in 3,000 participants. Not yet recruiting.

Timeline

1 January 2024

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Xuanwu Hospital, Beijing
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	3,000
Start date	1 January 2024
Primary completion	31 December 2026
Estimated completion	31 December 2027

Conditions studied

Severe Brain Injury — all drugs for Severe Brain Injury →

Sponsor

Xuanwu Hospital, Beijing

Who can join

18 and older, any sex, with Severe Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Building a Large Chinese Cohort(Chinese Severe brain injury Trial）

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Severe Brain Injury

Currently open trials in the same condition.

NCT06851156 — Transcranial Temporal Interference Stimulation In Severely Brain Injured Patients With Disorders of Consciousness · NA · recruiting
NCT06797752 — Effect of the Stellate Ganglion Block on the Retinal Microcirculation · recruiting

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06179836 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
Last refreshed: 22 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06179836.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing